Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]
<p>Abstract</p> <p>Background</p> <p>Prevention of preterm birth remains one of the most important challenges in maternity care. We propose a randomised trial with: a simple <it>Candida </it>testing protocol that can be easily incorporated into usual antenat...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-03-01
|
Series: | BMC Pregnancy and Childbirth |
Online Access: | http://www.biomedcentral.com/1471-2393/11/19 |
id |
doaj-4f72457759e14917aff0631b70432eef |
---|---|
record_format |
Article |
spelling |
doaj-4f72457759e14917aff0631b70432eef2020-11-24T23:57:15ZengBMCBMC Pregnancy and Childbirth1471-23932011-03-011111910.1186/1471-2393-11-19Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]Rickard Kristen RMorris Jonathan MRoberts Christine LGiles Warwick BSimpson Judy MKotsiou GeorgeBowen Jennifer R<p>Abstract</p> <p>Background</p> <p>Prevention of preterm birth remains one of the most important challenges in maternity care. We propose a randomised trial with: a simple <it>Candida </it>testing protocol that can be easily incorporated into usual antenatal care; a simple, well accepted, treatment intervention; and assessment of outcomes from validated, routinely-collected, computerised databases.</p> <p>Methods/Design</p> <p>Using a prospective, randomised, open-label, blinded-endpoint (PROBE) study design, we aim to evaluate whether treating women with asymptomatic vaginal candidiasis early in pregnancy is effective in preventing spontaneous preterm birth. Pregnant women presenting for antenatal care <20 weeks gestation with singleton pregnancies are eligible for inclusion. The intervention is a 6-day course of clotrimazole vaginal pessaries (100 mg) and the primary outcome is spontaneous preterm birth <37 weeks gestation.</p> <p>The study protocol draws on the usual antenatal care schedule, has been pilot-tested and the intervention involves only a minor modification of current practice. Women who agree to participate will self-collect a vaginal swab and those who are culture positive for Candida will be randomised (central, telephone) to open-label treatment or usual care (screening result is not revealed, no treatment, routine antenatal care). Outcomes will be obtained from population databases.</p> <p>A sample size of 3,208 women with <it>Candida </it>colonisation (1,604 per arm) is required to detect a 40% reduction in the spontaneous preterm birth rate among women with asymptomatic candidiasis from 5.0% in the control group to 3.0% in women treated with clotrimazole (significance 0.05, power 0.8). Analyses will be by intention to treat.</p> <p>Discussion</p> <p>For our hypothesis, a placebo-controlled trial had major disadvantages: a placebo arm would not represent current clinical practice; knowledge of vaginal colonisation with <it>Candida </it>may change participants' behaviour; and a placebo with an alcohol preservative may have an independent affect on vaginal flora. These disadvantages can be overcome by the PROBE study design.</p> <p>This trial will provide definitive evidence on whether screening for and treating asymptomatic candidiasis in pregnancy significantly reduces the rate of spontaneous preterm birth. If it can be demonstrated that treating asymptomatic candidiasis reduces preterm births this will change current practice and would directly impact the management of every pregnant woman.</p> <p>Trial registration</p> <p>Australian New Zealand Clinical Trials Registry <a href="http://www.anzctr.org.au/ACTRN12610000607077.aspx">ACTRN12610000607077</a></p> http://www.biomedcentral.com/1471-2393/11/19 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rickard Kristen R Morris Jonathan M Roberts Christine L Giles Warwick B Simpson Judy M Kotsiou George Bowen Jennifer R |
spellingShingle |
Rickard Kristen R Morris Jonathan M Roberts Christine L Giles Warwick B Simpson Judy M Kotsiou George Bowen Jennifer R Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077] BMC Pregnancy and Childbirth |
author_facet |
Rickard Kristen R Morris Jonathan M Roberts Christine L Giles Warwick B Simpson Judy M Kotsiou George Bowen Jennifer R |
author_sort |
Rickard Kristen R |
title |
Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077] |
title_short |
Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077] |
title_full |
Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077] |
title_fullStr |
Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077] |
title_full_unstemmed |
Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077] |
title_sort |
protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [actrn12610000607077] |
publisher |
BMC |
series |
BMC Pregnancy and Childbirth |
issn |
1471-2393 |
publishDate |
2011-03-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Prevention of preterm birth remains one of the most important challenges in maternity care. We propose a randomised trial with: a simple <it>Candida </it>testing protocol that can be easily incorporated into usual antenatal care; a simple, well accepted, treatment intervention; and assessment of outcomes from validated, routinely-collected, computerised databases.</p> <p>Methods/Design</p> <p>Using a prospective, randomised, open-label, blinded-endpoint (PROBE) study design, we aim to evaluate whether treating women with asymptomatic vaginal candidiasis early in pregnancy is effective in preventing spontaneous preterm birth. Pregnant women presenting for antenatal care <20 weeks gestation with singleton pregnancies are eligible for inclusion. The intervention is a 6-day course of clotrimazole vaginal pessaries (100 mg) and the primary outcome is spontaneous preterm birth <37 weeks gestation.</p> <p>The study protocol draws on the usual antenatal care schedule, has been pilot-tested and the intervention involves only a minor modification of current practice. Women who agree to participate will self-collect a vaginal swab and those who are culture positive for Candida will be randomised (central, telephone) to open-label treatment or usual care (screening result is not revealed, no treatment, routine antenatal care). Outcomes will be obtained from population databases.</p> <p>A sample size of 3,208 women with <it>Candida </it>colonisation (1,604 per arm) is required to detect a 40% reduction in the spontaneous preterm birth rate among women with asymptomatic candidiasis from 5.0% in the control group to 3.0% in women treated with clotrimazole (significance 0.05, power 0.8). Analyses will be by intention to treat.</p> <p>Discussion</p> <p>For our hypothesis, a placebo-controlled trial had major disadvantages: a placebo arm would not represent current clinical practice; knowledge of vaginal colonisation with <it>Candida </it>may change participants' behaviour; and a placebo with an alcohol preservative may have an independent affect on vaginal flora. These disadvantages can be overcome by the PROBE study design.</p> <p>This trial will provide definitive evidence on whether screening for and treating asymptomatic candidiasis in pregnancy significantly reduces the rate of spontaneous preterm birth. If it can be demonstrated that treating asymptomatic candidiasis reduces preterm births this will change current practice and would directly impact the management of every pregnant woman.</p> <p>Trial registration</p> <p>Australian New Zealand Clinical Trials Registry <a href="http://www.anzctr.org.au/ACTRN12610000607077.aspx">ACTRN12610000607077</a></p> |
url |
http://www.biomedcentral.com/1471-2393/11/19 |
work_keys_str_mv |
AT rickardkristenr protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 AT morrisjonathanm protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 AT robertschristinel protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 AT gileswarwickb protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 AT simpsonjudym protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 AT kotsiougeorge protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 AT bowenjenniferr protocolforarandomisedcontrolledtrialoftreatmentofasymptomaticcandidiasisforthepreventionofpretermbirthactrn12610000607077 |
_version_ |
1725454818553626624 |